Search clinical trials for: Factor Xa inhibitor treatment

Total 137468 results

Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Centre Hospitalier Universitaire de Saint Etienne
Takeda France

Not yet recruiting

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. (VEDIAN)

Crohn's Disease

France
AstraZeneca
Parexel

Recruiting

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment (REVERXaL)

Major Bleeding

United States, Japan, Germany, United Kingdom
AstraZeneca
LOGEX Healthcare Analytics Amsterdam The Netherlands

Recruiting

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Hemorrhage

Netherlands
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

Atrial Fibrillation

United States, Belgium, Italy, Japan, Taiwan, South Africa, Korea, Republic of, Poland, Chile, Serbia, Israel, France, Netherlands, Denmark, Hungary, Argentina, Australia, China, Spain, New Zealand, Czechia, Bulgaria, Croatia, Malaysia, German... and more
Imperial College London

Recruiting

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (THRIVE)

Varicose Veins | Venous Thromboembolism

United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, China, Spain, Italy, Germany, Belgium, Korea, Republic of, Poland, Taiwan, Israel, New Zealand, Sweden, United Kingdom, Japan, Czechia, Philippines, Hong Kong, Greece, Australia, Thailand, Netherlands, Argentina, Brazil, Fran... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
University Hospital, Montpellier

Recruiting

Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis (SEQUENS-RA)

Rheumatoid Arthritis

France, Monaco
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, China, Spain, Japan, Canada, Ireland, Italy, Korea, Republic of, France, Switzerland, Hungary, Netherlands, Latvia, Germany, Norway, Sweden, Czechia, United Kingdom
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
Vastra Gotaland Region
Göteborg University

Recruiting

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Takotsubo Syndrome

Norway, Denmark, Sweden
Asan Medical Center
Samsung Medical Center; Pusan National University Hospital; Chonnam National... and other collaborators

Recruiting

Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON) ((ADD-ON))

Atrial Fibrillation | Acute Ischemic Stroke | Anticoagulant | Coronary Artery Atherosclerosis | Intracranial Atherosclerosis | Extracranial Atherosclerosis | Antiplatelet | Peripheral Artery Stenosis

Korea, Republic of
The George Institute
Bayer; King Abdullah International Medical Research Center; George Clinical Pty... and other collaborators

Recruiting

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

Cardiovascular Disease | Chronic Kidney Diseases | Dialysis-dependent Kidney Failure

Taiwan, Australia, Malaysia, Tunisia, Singapore, Canada, France, India, Saudi Arabia
National Cancer Institute (NCI)

Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Down Syndrome | B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States, Canada, Puerto Rico, Australia, New Zealand
RenJi Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University and other collaborators

Recruiting

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT)

ST Segment Elevation Myocardial Infarction | Left Ventricular Thrombus

China
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Recruiting

Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (ROC-SPA)

Axial Spondyloarthritis

France, Monaco
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Recruiting

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA)

Venous Thromboembolism

Canada, Australia, Ireland
Lille Catholic University

Recruiting

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders (SUNSTAR)

Arthritis, Rheumatoid

France
Federation Francophone de Cancerologie Digestive

Recruiting

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR)

Colorectal Neoplasms

France, Switzerland
PETHEMA Foundation

Recruiting

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Acute Lymphoblastic Leukemia

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Korea, Republic of, Sweden, Japan, Poland, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

Urothelial Cancer

Korea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States
University of Edinburgh
Chief Scientist Office of the Scottish Government

Active, not recruiting

Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction (TARGET-Type 2)

Myocardial Infarction Type 2

United Kingdom
Bristol-Myers Squibb
Pfizer

Completed

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Venous Thromboembolism

United States, Spain, Canada, Austria, Germany, France, Australia, Mexico, United Kingdom, Israel, Russian Federation, Turkey, Ukraine
Pfizer
Bristol-Myers Squibb

Active, not recruiting

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Venous Thromboembolism

United States
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Treatment of Venous Thromboembolism in Cancer Patients

Sweden
Bayer

Completed

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Atrial Fibrillation | Prevention of Thromboembolic Events

United States
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Bayer

Completed

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort (OSCAR-US)

Treatment of Venous Thromboembolism in Cancer Patients | Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

United States
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer

Completed

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs (XATOC)

Coronary Artery Disease | Peripheral Artery Disease

Spain, Belgium, Italy, Korea, Republic of, Russian Federation, Taiwan, China, Colombia, Switzerland, Slovenia
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
Population Health Research Institute

Completed

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Ischemic Stroke | Intracranial Atherosclerotic Disease

Canada
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China
Pfizer

Completed

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Venous Thromboembolism

Korea, Republic of
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Daiichi Sankyo, Inc.

Completed

Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR)

Atrial Fibrillation

Turkey
Fundación de Investigación Biomédica - Hospital...

Active, not recruiting

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Atrial Fibrillation

Spain
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy (EDOI)

Cancer | Thromboembolism

Italy
Pfizer

Completed

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

Atrial Fibrillation

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
Arianna Anticoagulazione Foundation

Terminated

Apixaban for Extended Anticoagulation (APIDULCIS) (APIDULCIS)

Venous Thromboembolism | Anticoagulants

Italy

Search clinical trials for: Factor Xa inhibitor treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations